MADISON, Wis.

威斯康星州麦迪逊

,

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ -- CureC9, a patient-driven initiative dedicated to accelerating treatments for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), has partnered with BrainXell, Inc. to expand access to high-quality, patient-derived human iPSC models for the global research community..

/PRNewswire/ -- CureC9 是一项由患者推动的倡议，致力于加速研发针对 C9orf72 相关肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）的治疗方法。该倡议已与 BrainXell, Inc. 合作，为全球研究界扩大获取高质量、患者来源的人诱导多能干细胞（iPSC）模型的渠道。

The collaboration is built on a shared goal: connecting patients, researchers, nonprofit advocacy, and industry to remove barriers and accelerate discoveries for devastating neurodegenerative diseases.

此次合作基于一个共同目标：连接患者、研究人员、非营利倡导组织和产业界，以消除障碍并加速针对毁灭性神经退行性疾病的发现。

As part of the initiative, Yentli Soto Albrecht, PhD, Co-Founder of CureC9 and an MD-PhD Candidate at the Perelman School of Medicine at the University of Pennsylvania, and her late father have donated skin cells to BrainXell to establish the first patient-derived cell lines in a growing C9orf72 biorepository.

作为该倡议的一部分，CureC9 联合创始人、宾夕法尼亚大学佩雷尔曼医学院医学博士-哲学博士候选人 Yentli Soto Albrecht 博士与其已故父亲向 BrainXell 捐赠了皮肤细胞，以在日益扩大的 C9orf72 生物样本库中建立首批患者来源的细胞系。

These cells will be reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into disease-relevant CNS cell types—including motor neurons, astrocytes, and microglia—to provide researchers with standardized, commercially available models..

这些细胞将被重编程为诱导多能干细胞（iPSCs），并分化为与疾病相关的中枢神经系统细胞类型——包括运动神经元、星形胶质细胞和小胶质细胞，从而为研究人员提供标准化且可商业获得的模型。

'BrainXell was one of the first organizations to partner with me in my effort to accelerate a cure in my lifetime,' said Soto Albrecht. 'Together, we're creating a resource that helps researchers spend less time overcoming barriers and more time advancing treatments for patients.'

“BrainXell 是最早与我合作、致力于在我有生之年加速实现治愈目标的组织之一，”索托·阿尔布雷希特表示。“我们携手打造一个资源平台，帮助研究人员减少克服障碍的时间，将更多精力投入到推进患者治疗方案的研发中。”

The partnership also establishes a new model for patient engagement in research. Individuals and families affected by C9orf72-associated disease will have the opportunity to contribute biological samples to expand the repository, while a portion of proceeds from the program will support CureC9's ongoing mission to accelerate research and empower the patient community..

该合作伙伴关系还为患者参与研究建立了新模式。受C9orf72相关疾病影响的个人和家庭将有机会提供生物样本，以扩充样本库；同时，该项目的一部分收益将支持CureC9持续推动研究加速并赋能患者社区的使命。

Together, the organizations are creating a unique resource that empowers academic and industry researchers alike to better understand disease biology, evaluate new therapeutic approaches, and ultimately accelerate the search for effective treatments for ALS and FTD.

这些组织携手打造了一个独特的资源平台，使学术界和工业界的研究人员都能更好地认识疾病生物学机制，评估新的治疗方法，并最终加快寻找针对肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）的有效治疗方案的进程。

About CureC9

关于 CureC9

CureC9 is a patient-driven initiative focused on accelerating therapies for C9orf72-associated ALS and FTD by reducing barriers to research, expanding access to disease-relevant resources, and fostering collaboration between patients, scientists, clinicians, nonprofits, and industry. For more information, please visit curec9.com..

CureC9 是一项由患者主导的倡议，旨在通过降低研究壁垒、扩大疾病相关资源的获取渠道，并促进患者、科学家、临床医生、非营利组织及行业之间的合作，加速针对 C9orf72 相关肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）的疗法研发。如需更多信息，请访问 curec9.com。

SOURCE BrainXell, Inc

来源：BrainXell, Inc

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示